MedTrace Logo

Effect of Tegoprazan for Elective Surgery Patients Under General Anesthesia

NCT06743243 · Status: ENROLLING_BY_INVITATION · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 174

Last updated 2025-09-05

No results posted yet for this study

Summary

The aim of this study is to compare gastric pH right after endotracheal intubation for general anesthesia in patients pretreated with tegoprazan, famotidine, or placebo.

Conditions

  • General Anesthesia

Interventions

DRUG

Tegoprazan

Tegoprazan OD tab. 50 mg PO + Saline 20ml IV, one hour before general anesthesia.

DRUG

Famotidine

Famotidine 20mg/10ml+saline 10ml IV + Tegoprazan OD tab. 50 mg placebo PO, one hour before general anesthesia.

DRUG

Placebo

Tegoprazan OD tab. 50 mg placebo PO + Saline 20ml IV, one hour before general anesthesia.

Sponsors & Collaborators

  • Korea University Guro Hospital

    collaborator OTHER

  • HK inno.N Corporation

    collaborator INDUSTRY

  • Eunpyeong St. Mary's Hospital, The Catholic University of Korea

    collaborator UNKNOWN

  • Asan Medical Center

    collaborator OTHER

  • Seok Kyeong Oh

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
69 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-23
Primary Completion
2026-10-30
Completion
2026-12-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06743243 on ClinicalTrials.gov